Adaptimmune Therapeutics PLC (ADAPY): Total Liabilities
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$234.11M
As of 2024-12-31
$201.59M
As of 2025-06-30
-3.9%
3-year compound annual growth
+32.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $234.11M | -3.7% | 2025-03-24, Balance as of period end |
| 2023-12-31 | $243.10M | -1.6% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $247.04M | -6.3% | 2024-03-06, Balance as of period end |
| 2021-12-31 | $263.58M | +139.8% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $109.92M | +89.8% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $57.91M | +94.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $29.85M | -61.8% | 2020-02-27, Balance as of period end |
| 2017-12-31 | $78.16M | +14.3% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $68.37M | +34.5% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $50.83M | n/a | 2017-03-13, Balance as of period end |
| 2015-06-30 | $41.65M | n/a | 2017-03-13, Balance as of period end |